Show simple item record

dc.contributor.authorBowers, Jolene
dc.contributor.authorDriebe, Elizabeth
dc.contributor.authorNibecker, Jennifer
dc.contributor.authorWojack, Bette
dc.contributor.authorSarovich, Derek
dc.contributor.authorWong, Ada
dc.contributor.authorBrzoska, Pius
dc.contributor.authorHubert, Nathaniel
dc.contributor.authorKnadler, Andrew
dc.contributor.authorWatson, Lindsey
dc.contributor.authorWagner, David
dc.contributor.authorFurtado, Manohar
dc.contributor.authorSaubolle, Michael
dc.contributor.authorEngelthaler, David
dc.contributor.authorKeim, Paul
dc.date.accessioned2016-05-20T08:57:34Z
dc.date.available2016-05-20T08:57:34Z
dc.date.issued2012en
dc.identifier.citationBowers et al. BMC Microbiology 2012, 12:12 http://www.biomedcentral.com/1471-2180/12/12en
dc.identifier.doi10.1186/1471-2180-12-12en
dc.identifier.urihttp://hdl.handle.net/10150/610057
dc.description.abstractBACKGROUND:Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.RESULTS:Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.CONCLUSIONS:The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.biomedcentral.com/1471-2180/12/12en
dc.rights© 2012 Bowers et al; BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).en
dc.rights.urihttps://creativecommons.org/licenses/by/2.0/
dc.titleDominance of multidrug resistant CC271 clones in macrolide-resistant Streptococcus pneumoniae in Arizonaen
dc.typeArticleen
dc.identifier.eissn1471-2180en
dc.contributor.departmentTranslational Genomics Research Institute, Flagstaff, AZ, USAen
dc.contributor.departmentLaboratory Sciences of Arizona, Tempe, AZ, USAen
dc.contributor.departmentNorthern Arizona University, Flagstaff, AZ, USAen
dc.contributor.departmentLife Technologies, Foster City, CA, USAen
dc.contributor.departmentUniversity of Arizona, Tucson, AZ, USAen
dc.identifier.journalBMC Microbiologyen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-06-28T22:34:16Z
html.description.abstractBACKGROUND:Rates of resistance to macrolide antibiotics in Streptococcus pneumoniae are rising around the world due to the spread of mobile genetic elements harboring mef(E) and erm(B) genes and post-vaccine clonal expansion of strains that carry them.RESULTS:Characterization of 592 clinical isolates collected in Arizona over a 10 year period shows 23.6% are macrolide resistant. The largest portion of the macrolide-resistant population, 52%, is dual mef(E)/erm(B)-positive. All dual-positive isolates are multidrug-resistant clonal lineages of Taiwan19F-14, mostly multilocus sequence type 320, carrying the recently described transposon Tn2010. The remainder of the macrolide resistant S. pneumoniae collection includes 31% mef(E)-positive, and 9% erm(B)-positive strains.CONCLUSIONS:The dual-positive, multidrug-resistant S. pneumoniae clones have likely expanded by switching to non-vaccine serotypes after the heptavalent pneumococcal conjugate vaccine release, and their success limits therapy options. This upsurge could have a considerable clinical impact in Arizona.


Files in this item

Thumbnail
Name:
1471-2180-12-12.pdf
Size:
349.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2012 Bowers et al; BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).
Except where otherwise noted, this item's license is described as © 2012 Bowers et al; BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).